Evolution of HLA‐sensitization according to immunosuppressive therapy management among kidney transplant patients returning to dialysis between 2008 and 2019: A French retrospective study

Abstract

AbstractBackgroundThe optimal management of immunosuppressive therapy (IT) after kidney allograft failure (KAF) remains controversial. Although maintaining IT may reduce HLA‐sensitization and improve access to retransplantation, it may also increase the rate of immunosuppression‐related complications. The overall impact on patient mortality is unknown. The main objective of this study was to compare the evolution of HLA‐sensitization 6 months after KAF according to IT management.MethodsIndividual clinical and health care data were extracted from the French national end‐stage kidney disease registry (Renal Epidemiology and Information Network [REIN]) and the French National Health Data system (SNDS), respectively. Patients aged > 18 years returning to dialysis after KAF between January 2008 and December 2019 in Lorraine were included. Patients were classified into two groups, IT continuation or IT discontinuation. HLA‐sensitization was defined as an increase in incompatible graft rate (IGR) between KAF and 6 months post‐KAF (change to a higher predefined category (0%–5%), (5%–20%), (20%–50%), (50%–85%), (85%–95%), (95%–98%), (98%–100%)). Secondary outcome was patient survival according to IT management.ResultsA total of 121 patients were included, 35 (29%) of whom continued IT. HLA‐sensitization after KAF tended to be higher in the “IT discontinuation” group (57% vs. 38% in the “IT continuation” group, p = .07). In multivariate analysis, IT continuation was associated with a lower increase in IGR (OR .37, 95% CI [.14; .93]). IT management was not associated with patient mortality.ConclusionsContinuation of IT after KAF was associated with less change in IGR and was not associated with excess mortality.